Annovis Bio partners with Weave Bio on AI platform to support planned buntanetap Alzheimer’s NDA submission
Bitget2026/09/23 12:02- Annovis Bio entered a collaboration with Weave Bio to support preparation of a planned U.S. NDA for Alzheimer’s drug candidate buntanetap.
- Weave’s AI platform will be used to draft, review, and manage NDA documents ahead of the Phase 3 trial’s 6-month top-line readout.
- Annovis retains responsibility for content, verification, and final approval of all documents submitted to the FDA.
- The pivotal Phase 3 Alzheimer’s study enrolled 862 biomarker-confirmed patients versus a 760 target.
- Database lock is targeted for December 2026; top-line symptomatic data are expected in March 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Crypto prices
More
